Clinical Trial Detail

NCT ID NCT01479244
Title Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Galena Biopharma, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

E75

Sargramostim

Age Groups: adult

Additional content available in CKB BOOST